Alpha 2.0
Login Register
» Articles » PMID: 34758264

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2021 Nov 10
PMID 34758264
Citations 10
Authors
Viral N Shah
Laura Pyle
Affiliations
Soon will be listed here.
Citing Articles

Advances in Diagnosis and Treatment of Inherited Kidney Diseases in Children.

Wang G, Liao M, Tan D, Chen X, Chao R, Zhu Y Kidney Dis (Basel). 2024; 10(6):558-572.

PMID: 39664340 PMC: 11631113. DOI: 10.1159/000541564.

Technologies for Targeted RNA Degradation and Induced RNA Decay.

Mikutis S, Bernardes G Chem Rev. 2024; 124(23):13301-13330.

PMID: 39499674 PMC: 11638902. DOI: 10.1021/acs.chemrev.4c00472.

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.

Lilja J, Kaivola J, Conway J, Vuorio J, Parkkola H, Roivas P Nat Commun. 2024; 15(1):8002.

PMID: 39266533 PMC: 11393128. DOI: 10.1038/s41467-024-52326-1.

RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.

Ganesh S, Kim M, Lee J, Feng X, Ule K, Mahan A Mol Ther. 2024; 32(6):1895-1916.

PMID: 38549376 PMC: 11184339. DOI: 10.1016/j.ymthe.2024.03.035.

Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1.

Zheng R, Zhang D, Shao Y, Fang X, Yang L, Huo Y Zool Res. 2023; 44(6):993-1002.

PMID: 37759334 PMC: 10802098. DOI: 10.24272/j.issn.2095-8137.2022.495.